- Price
- $110.40
- Day
- +4.13%
- Mkt Cap
- $4.61B
- 52W Range
- $18.08 – $114.55
- Volume
- 622.5K
- Beta
- 0.08
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanisms DNTH312 demonstrated comparable in vitro potency and aC1s inhibition to claseprubart, with a comparable non-human primate (NHP) half-life DNTH312 showed similar depth of Ig reductions vs. povetacicept following a single dose in NHPs By building on claseprubart's best-in-class profile, DNTH312 strengthens Dianthus' leadership in neuromuscular disease, while expanding into additional autoimmune diseases where both B cell modulation and Classical Pathway inhibition could provide additional benefits to more patients DNTH312 aims to be Phase 1 ready by YE'27 NEW YORK and WALTHAM, Mass.
Read full article
Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN) Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W initiated in June ‘26, with top-line results anticipated in 2H'28 75% response rate observed in Interim Responder Analysis from first 40 participants completing Part A of Phase 3 CAPTIVATE trial of claseprubart in CIDP, with Part B top-line guidance expected by YE'26 Phase 2 MoMeNtum trial of claseprubart in MMN exceeded its original enrollment target of 36 patients; top-line results with 46 patients on track for December '26 Building a rheumatology franchise with DNTH212 across our first three prioritized indications of Sjögren's Disease (SjD), Systemic Lupus Erythematosus (SLE), and Dermatomyositis (DM); Phase 1 healthy volunteer data anticipated by YE'26 Advancing DNTH312, an internally developed, first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI to target potent inhibition of aC1s and BAFF/APRIL for severe autoimmune diseases; DNTH312 aims to be Phase 1 ready by YE'27 Approximately $1.2 billion of cash as of June 30, 2026 provides expected runway into 2030 NEW YORK and WALTHAM, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today reported financial results for the second quarter ending June 30, 2026, and provided an update on other recent business achievements.
Read full article
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to a loss of $0.88 per share a year ago.
Read full article
NEW YORK and WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on August 3, 2026, to six newly-hired, non-executive employees.
Read full article